News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 08 - 21

Joint Efforts! 3D Medicines and Canton Biologics Forge Alliance to Advance tLNP-Delivered in vivo CA

On August 20, 2025, in Shanghai, China, 3D Medicines and Canton Biologics officially signed a strategic cooperation agreement. According to the agreement, the two parties will deepen their collaboration in areas such as targeted lipid nanoparticle (tLNP) delivery, tumor vaccines, and in vivo CAR-T/NK therapies. This collaboration will leverage 3D Medicines' self-developed, proprietary AI+mRNA R&D platform and liposome delivery system (3D-LNP), combined with Canton Biologics' expertise and scale in mRNA manufacturing. The specific implementation will follow subsequent form...

浏览次数：2

查看详情>>

发布时间: 2025 - 08 - 20

Closed-Loop Neuromodulation: The Advanced Logic of Non-Invasive Brain-Computer Interfaces | Ef Capit

A Brain-Computer Interface (BCI) is defined as a system where, when a user actively performs specific mental tasks or receives specific external stimuli, sensor technology acquires signals generated by the central nervous system. Features of brain signals representing or encoding the user's intent are directly converted into communication and control commands for interacting with a computer-centric machine system. The results of the interaction are then fed back to the user to regulate their mental activity strategies.Based on the invasiveness of electrode placement, BCIs can be categorize...

浏览次数：4

查看详情>>

发布时间: 2025 - 08 - 15

Progen's Recombinant Human Serum Albumin Injection Achieves Key Progress in Phase III Study

Recently, the pivotal Phase III clinical study of Progen's fully in-house developed Recombinant Human Serum Albumin (rHSA) Injection for the indication of cirrhosis-induced ascites successfully met the primary efficacy endpoint and key secondary efficacy endpoints required by the National Medical Products Administration (NMPA). The New Drug Application (NDA) for market approval has been fully initiated.The Phase III clinical study of Progen's Recombinant Human Serum Albumin Injection for the cirrhosis-induced ascites indication adopted a multi-center, randomized, double-blind, active-c...

浏览次数：0

查看详情>>

发布时间: 2025 - 08 - 14

Efung Capital CEO Zhu Pui Honored on Fortune China's 2025 "40 Under 40" Most Promising Business Elit

Recently, Fortune (Chinese edition) released its "China's 40 Under 40 Business Elite" list. Zhu Pui, CEO of Efung Capital, was honored on Fortune China's 2025 "40 Under 40" Most Promising Business Elite list, showcasing the forward-looking vision and business acumen of the younger generation of entrepreneurs.This year's list continues the dual-track selection mechanism from previous years, featuring both the "China's 40 Under 40 Business Elite" list and the "China's 40 Under 40 Most Promising Business Elite" list. The former recognize...

浏览次数：1

查看详情>>